European Commission Approves Two New Regimens of Merck?s KEYTRUDA(pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
KEYTRUDA is the First Anti-PD-1 Therapy Approved in Europe for the First-Line Treatment of Head and Neck Cancer as Monotherapy or in Combination with Chemotherapy, in Patients Whose Tumors Express PD-L1 (CPS =1)
Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial
- KEYTRUDA 200 mg intravenously every three weeks;
- KEYTRUDA 200 mg intravenously every three weeks, carboplatin AUC 5 mg/mL/min intravenously every three weeks or cisplatin 100 mg/m2?intravenously every three weeks and 5-FU 1000 mg/m2/day as a continuous intravenous infusion over 96 hours every three weeks (maximum of six cycles of platinum and 5-FU);
- Cetuximab 400 mg/m2?intravenously as the initial dose then 250 mg/m2?intravenously once weekly, carboplatin AUC 5 mg/mL/min intravenously every three weeks or cisplatin 100 mg/m2?intravenously every three weeks and 5-FU 1000 mg/m2/day as a continuous intravenous infusion over 96 hours every three weeks (maximum of six cycles of platinum and 5-FU).
Efficacy Results for KEYTRUDA as Monotherapy in KEYNOTE-048 with PD-L1 Expression (CPS =1) |
||||
Endpoint |
KEYTRUDA n=257 |
Standard Treatment* n=255 |
||
OS |
||||
Number (%) of patients with event |
197 (77%) |
229 (90%) |
||
Median in months (95% CI) |
12.3 (10.8, 14.3) |
10.3 (9.0, 11.5) |
||
Hazard ratio??(95% CI) |
0.74 (0.61, 0.90) |
|||
p-Value? |
0.00133 |
|||
PFS |
||||
Number (%) of patients with event |
228 (89%) |
237 (93%) |
||
Median in months (95% CI) |
3.2 (2.2, 3.4) |
5.0 (4.8, 6.0) |
||
Hazard ratio??(95% CI) |
1.13 (0.94, 1.36) |
|||
p-Value? |
0.89580 |
|||
ORR |
||||
Objective response rate??(95% CI) |
19.1% (14.5, 24.4) |
35% (29.1, 41.1) |
||
Complete response |
5% |
3% |
||
Partial response |
14% |
32% |
||
p-Value? |
1.0000 |
|||
Duration of Response |
||||
Median in months (range) |
23.4 (1.5+, 43.0+) |
4.5 (1.2+, 38.7+) |
||
% with duration =6 months |
81% |
36% |
* |
Cetuximab, platinum, and 5-FU |
? |
Based on the stratified Cox proportional hazard model |
? |
Based on stratified log-rank test |
? |
Response: Best objective response as confirmed complete response or partial response |
? |
Based on Miettinen and Nurminen method stratified by ECOG (0 vs. 1), HPV status (positive vs. negative) and PD-L1 status (strongly positive vs. not strongly positive) |
Efficacy Results for KEYTRUDA plus Chemotherapy in KEYNOTE-048 with PD-L1 Expression (CPS =1) |
||||
Endpoint |
KEYTRUDA + Platinum Chemotherapy + 5-FU n=242 |
Standard Treatment* n=235 |
||
OS |
||||
Number (%) of patients with event |
177 (73%) |
213 (91%) |
||
Median in months (95% CI) |
13.6 (10.7, 15.5) |
10.4 (9.1, 11.7) |
||
Hazard ratio??(95% CI) |
0.65 (0.53, 0.80) |
|||
p-Value? |
0.00002 |
|||
PFS |
||||
Number (%) of patients with event |
212 (88%) |
221 (94%) |
||
Median in months (95% CI) |
5.1 (4.7, 6.2) |
5.0 (4.8, 6.0) |
||
Hazard ratio??(95% CI) |
0.84 (0.69, 1.02) |
|||
p-Value? |
0.03697 |
|||
ORR |
||||
Objective response rate??(95% CI) |
36% (30.3, 42.8) |
36% (29.6, 42.2) |
||
Complete response |
7% |
3% |
||
Partial response |
30% |
33% |
||
p-Value? |
0.4586 |
|||
Duration of Response |
||||
Median in months (range) |
6.7 (1.6+, 39.0+) |
4.3 (1.2+, 31.5+) |
||
% with duration =6 months |
54% |
34% |
* |
Cetuximab, platinum, and 5-FU |
? |
Based on the stratified Cox proportional hazard model |
? |
Based on stratified log-rank test |
? |
Response: Best objective response as confirmed complete response or partial response |
? |
Based on Miettinen and Nurminen method stratified by ECOG (0 vs. 1), HPV status (positive vs. negative) and PD-L1 status (strongly positive vs. not strongly positive |
- solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or
- colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan.
Share this article on WhatsApp, LinkedIn and Twitter
Incisive News in 3 Shots.
Contact Us
- First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
- +91-120 428 0707
- connect@pharmashots.com
- Newsletter
Our Information
Modal title
Modal body text goes here.